Feb 24, 2025 | Korea Biomedical Review
Korea Biomedical Reviewㅣ 2024-01-20 SAN FRANCISCO, Calif. — By Kim Chan-hyuk/Korea Biomedical Review correspondent — Mediwhale is accelerating its global expansion, starting with supplying its “Dr. Noon CVD” to Glucare, a diabetes clinic in Dubai, last...Dec 17, 2024 | Korea Biomedical Review
Korea Biomedical Reviewㅣ 2024-12-17 November 18, 2024 marked a critical day for Mediwhale, a Korean medical AI company with ambitions to transform cardiovascular disease detection. The company’s third pre-submission meeting with the U.S. FDA had just concluded, and...Nov 18, 2024 | Korea Biomedical Review, Uncategorized
Korea Biomedical Reviewㅣ 2024-11-15 Medical AI company Mediwhale will release three research abstracts on its AI-powered cardiovascular disease (CVD) prediction software, Reti-CVD, at the American Heart Association’s (AHA) Scientific Sessions 2024, which will be held...Oct 30, 2024 | Korea Biomedical Review
Korea Biomedical Reviewㅣ 2024-10-30 Mediwhale said Wednesday that it has won first place in two categories at the Medical AI Competition organized by the Medical Image Computing and Computer Assisted Intervention (MICCAI). MICCAI is the most prestigious conference in...Sep 26, 2024 | Korea Biomedical Review
Korea Biomedical Reviewㅣ 2024-09-04 For 25 years, Choi Tae-geun, CEO of the Korean medical AI company Mediwhale, lived under the illusion of perfect health. But just before turning 26, a routine eye exam with Professor Rim Hyung-taek, who currently serves as the...Jun 28, 2024 | Korea Biomedical Review, Uncategorized
Korea Biomedical Review | 2024-06-27 Mediwhale, a medical AI diagnostic solution provider, said Thursday that it has been selected as a “JLABS” company, benefitting from a global accelerator platform operated by Johnson & Johnson Innovation, a multinational...